Nicotibine (Isoniazid)

Isoniazid, the active ingredient in Nicotibine, is an antitubercular agent presented as an oral dosage form for oral use. It is employed in the treatment of active tuberculosis and in the prophylaxis of latent Mycobacterium tuberculosis infection in adults and children.

GNH USA supplies Nicotibine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Isoniazid is used in the antitubercular drug class to manage infections caused by Mycobacterium tuberculosis.

Tuberculosis: Reduces bacterial load and promotes cure of active pulmonary and extrapulmonary disease. Latent TB infection prophylaxis: Prevents progression from latent infection to active disease in high‑risk individuals.

Isoniazid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Loss of appetite - Peripheral neuropathy - Rash - Fever

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe allergic reactions (anaphylaxis, angioedema) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Drug‑induced lupus erythematosus - Seizures - Hematologic abnormalities (anemia, leukopenia)

When prescribing Nicotibine, clinicians should consider several safety measures.

Liver function monitoring: Perform baseline and periodic liver enzyme tests, especially in patients with pre‑existing hepatic disease. Alcohol consumption: Advise patients to limit alcohol intake to reduce risk of hepatotoxicity. Peripheral neuropathy risk: Supplement with pyridoxine (vitamin B6) to prevent nerve damage. Pregnancy and lactation: Use only if benefits outweigh risks; assess on a case‑by‑case basis. Drug resistance: Ensure adherence to full treatment course to prevent emergence of resistant Mycobacterium strains. Store at ambient temperature: Keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Isoniazid interacts with several medicines that may alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Rifampicin: Induces hepatic enzymes, markedly lowering isoniazid plasma concentrations. - Phenytoin: Increases neurotoxic risk and may reduce isoniazid efficacy. - Alcohol: Synergistic hepatotoxic effect, heightening liver injury risk.

Moderate Interactions (Monitor Closely): - Carbamazepine: May increase neurotoxicity; monitor neurological status. - Pyrazinamide: Combined hepatotoxic potential; check liver function regularly. - Acetylcysteine: May alter isoniazid metabolism; adjust monitoring as needed.